Last reviewed · How we verify
Avandia and Amaryl
This combination uses rosiglitazone (Avandia) to increase insulin sensitivity and glimepiride (Amaryl) to stimulate insulin secretion, together lowering blood glucose in type 2 diabetes.
This combination uses rosiglitazone (Avandia) to increase insulin sensitivity and glimepiride (Amaryl) to stimulate insulin secretion, together lowering blood glucose in type 2 diabetes. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Avandia and Amaryl |
|---|---|
| Also known as | rosiglitazone maleate and glimepiride, Avandia (rosiglitazone maleate) 4 mg, Avandia (rosiglitazone maleate) 8 mg, Amaryl (glimepiride) 1 mg, Amaryl (glimepiride) 2 mg |
| Sponsor | Canadian Heart Research Centre |
| Drug class | Thiazolidinedione + Sulfonylurea combination |
| Target | PPAR-γ (rosiglitazone); Sulfonylurea receptor / ATP-sensitive potassium channel (glimepiride) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Rosiglitazone is a thiazolidinedione that activates peroxisome proliferator-activated receptor gamma (PPAR-γ), improving insulin sensitivity in muscle and fat tissues. Glimepiride is a sulfonylurea that stimulates pancreatic beta cells to release more insulin. The combination addresses both insulin resistance and insufficient insulin production in type 2 diabetes.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Weight gain
- Fluid retention / edema
- Heart failure exacerbation
Key clinical trials
- Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT) (PHASE3)
- Action to Control Cardiovascular Risk in Diabetes (ACCORD) (PHASE3)
- Efficacy and Safety of Dapagliflozin in Combination With Glimepiride (a Sulphonylurea) in Type 2 Diabetes Patients (PHASE3)
- Avandia™ + Amaryl™ or Avandamet™ Compared With Metformin (AVALANCHE™ Study) (PHASE3)
- An Efficacy and Safety Study of Fixed-dose Rosiglitazone/Glimepiride to Treat Chinese Type 2 Diabetes Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Avandia and Amaryl CI brief — competitive landscape report
- Avandia and Amaryl updates RSS · CI watch RSS
- Canadian Heart Research Centre portfolio CI